Now looking beyond NASH, PEMB has the potential to address major unmet medical needs in both AUD and ALD because of a similar ...

David Kindness is a Certified Public Accountant (CPA) and an expert in the fields of financial accounting, corporate and individual tax planning and preparation, and investing and retirement planning.

Novo Nordisk A/S remains a Buy despite CagriSema setback; Eli Lilly and Company remains a Hold on valuation. Click for this ...

Discover Vivani Medical's GLP-1 implant offering steady, reversible drug delivery to enhance adherence and reduce unnecessary ...

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...

Altimmune (ALT) is advancing pemvidutide, a dual GLP-1/glucagon agonist, into a pivotal Phase 3 MASH trial in 2026.

Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will present two posters featuring real-world data from its portfolio of differentiated pain medications at PainConnect 2026, the ...